Search
Selected Filter
Filter Results
Displaying 181–190 of 487 news results
-
May 24, 2021
Investigators Report Partial Vision Restoration for One Patient in Optogenetic Therapy Trial
The gene-agnostic approach is designed to restore some vision to people with advanced vision loss
-
May 21, 2021
New Bipartisan Legislation Introduced to Boost Clinical Research for Treatments and Cures
The bill would provide loans to therapy developers ready to launch clinical trials for a broad range of conditions including eye diseases.
-
May 21, 2021
Foundation Fighting Blindness Applauds Introduction of LOANS for Biomedical Research Act
Legislation provides innovative financing for clinical trials stalled by COVID-19 pandemic.
-
May 20, 2021
The free webinar for eye care professionals, on June 21, will feature some of the intriguing and innovative research efforts underway for inherited retinal diseases and AMD.
An overview of the Foundation’s no-cost genetic testing program will also be presented.
-
May 18, 2021
Uses novel, mutation agnostic optogenetics approach to restore vision in underserved forms of blindness. Company backed by leading life science investors including Octagon Capital, Samsara BioCapital and Casdin Capital, along with founding investors Atlas Venture, Mission BioCapital and Foundation Fighting Blindness.
-
May 14, 2021
Biogen’s Phase 2/3 Clinical Trial for XLRP Gene Therapy Doesn’t Meet Primary Endpoint
More details from the clinical trial will be reported at a later date
-
May 10, 2021
AGTC Continues to Report Encouraging Data from its Phase 1/2 XLRP Gene Therapy Clinical Trial
The company is planning the launch of a Phase 2/3 trial for its XLRP gene therapy
-
May 10, 2021
Precise and Sensitive Outcome Measures are Essential for Getting Vision Treatments through Clinical Trials
-
May 5, 2021
ARVO 2021 Highlight: CRISPR/Cas9 Therapy Emerging for Dominant RP Caused by RP1 Mutations
Gene-editing approaches are often better suited for autosomal dominant retinal diseases than gene replacement therapies
-
May 3, 2021
ARVO 2021 Highlight: Update on Clinical Trial of jCyte’s Cellular Therapy for RP
Cellular treatment provided significant improvements in visual acuity for subpopulation of patients with better vision